## Sergio Sosa-Estani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1773657/publications.pdf

Version: 2024-02-01

41 papers

3,179 citations

236925 25 h-index 302126 39 g-index

44 all docs

44 docs citations

times ranked

44

2622 citing authors

#	Article	IF	CITATIONS
1	Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. New England Journal of Medicine, 2015, 373, 1295-1306.	27.0	807
2	Benznidazole and Posaconazole inÂEliminating Parasites in Asymptomatic T.ÂCruzi Carriers. Journal of the American College of Cardiology, 2017, 69, 939-947.	2.8	231
3	Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: The BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). American Heart Journal, 2008, 156, 37-43.	2.7	183
4	Analytical Validation of Quantitative Real-Time PCR Methods for Quantification of Trypanosoma cruzi DNA in Blood Samples from Chagas Disease Patients. Journal of Molecular Diagnostics, 2015, 17, 605-615.	2.8	153
5	Trypanocide Treatment of Women Infected with Trypanosoma cruzi and Its Effect on Preventing Congenital Chagas. PLoS Neglected Tropical Diseases, 2014, 8, e3312.	3.0	152
6	Congenital Chagas Disease: Recommendations for Diagnosis, Treatment and Control of Newborns, Siblings and Pregnant Women. PLoS Neglected Tropical Diseases, 2011, 5, e1250.	3.0	148
7	Congenital Chagas disease: an update. Memorias Do Instituto Oswaldo Cruz, 2015, 110, 363-368.	1.6	115
8	New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial. Lancet Infectious Diseases, The, 2021, 21, 1129-1140.	9.1	101
9	Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina. Current Opinion in Infectious Diseases, 2006, 19, 583-587.	3.1	93
10	Etiological treatment of young women infected with Trypanosoma cruzi, and prevention of congenital transmission. Revista Da Sociedade Brasileira De Medicina Tropical, 2009, 42, 484-487.	0.9	88
11	Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review. Expert Review of Anti-Infective Therapy, 2014, 12, 479-496.	4.4	88
12	Clinical and pharmacological profile of benznidazole for treatment of Chagas disease. Expert Review of Clinical Pharmacology, 2018, 11, 943-957.	3.1	84
13	Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America. Expert Review of Anti-Infective Therapy, 2019, 17, 145-157.	4.4	77
14	WHF IASC Roadmap on Chagas Disease. Global Heart, 2020, 15, 26.	2.3	75
15	Therapy, diagnosis and prognosis of chronic Chagas disease: insight gained in Argentina. Memorias Do Instituto Oswaldo Cruz, 2009, 104, 167-180.	1.6	71
16	New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: a Pilot Short-Term Follow-Up Study with Adult Patients. Antimicrobial Agents and Chemotherapy, 2016, 60, 833-837.	3.2	67
17	Target Product Profile (TPP) for Chagas Disease Point-of-Care Diagnosis and Assessment of Response to Treatment. PLoS Neglected Tropical Diseases, 2015, 9, e0003697.	3.0	63
18	The burden of congenital Chagas disease and implementation of molecular diagnostic tools in Latin America. BMJ Global Health, 2018, 3, e001069.	4.7	50

#	Article	IF	CITATIONS
19	Congenital Transmission of Trypanosoma cruzi in Argentina, Honduras, and Mexico: An Observational Prospective Study. American Journal of Tropical Medicine and Hygiene, 2018, 98, 478-485.	1.4	48
20	Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies. PLoS ONE, 2015, 10, e0139363.	2.5	43
21	COVID-19: Implications for People with Chagas Disease. Global Heart, 2020, 15, 69.	2.3	39
22	Early Diagnosis of Congenital Trypanosoma cruzi Infection, Using Shed Acute Phase Antigen, in Ushuaia, Tierra del Fuego, Argentina. American Journal of Tropical Medicine and Hygiene, 2010, 82, 55-59.	1.4	36
23	Cultural barriers to effective communication between Indigenous communities and health care providers in Northern Argentina: an anthropological contribution to Chagas disease prevention and control. International Journal for Equity in Health, 2014, 13, 6.	3.5	35
24	Implications of asymptomatic infection for the natural history of selected parasitic tropical diseases. Seminars in Immunopathology, 2020, 42, 231-246.	6.1	34
25	Comparative Study and Analytical Verification of PCR Methods for the Diagnosis of Congenital Chagas Disease. Journal of Molecular Diagnostics, 2017, 19, 673-681.	2.8	30
26	Integrated control of Chagas disease for its elimination as public health problem - A Review. Memorias Do Instituto Oswaldo Cruz, 2015, 110, 289-298.	1.6	29
27	Therapy of Chagas Disease: Implications for Levels of Prevention. Journal of Tropical Medicine, 2012, 2012, 1-10.	1.7	28
28	Course of serological tests in treated subjects with chronic Trypanosoma cruzi infection: A systematic review and meta-analysis of individual participant data. International Journal of Infectious Diseases, 2018, 73, 93-101.	3.3	27
29	Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus. PLoS Neglected Tropical Diseases, 2020, 14, e0008035.	3.0	26
30	Chagas disease control-surveillance in the Americas: the multinational initiatives and the practical impossibility of interrupting vector-borne Trypanosoma cruzi transmission. Memorias Do Instituto Oswaldo Cruz, 0, $117$ , .	1.6	26
31	The translational challenge in Chagas disease drug development. Memorias Do Instituto Oswaldo Cruz, 0, 117, .	1.6	21
32	New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: Clinical, Parasitological, and Serological Assessment after Three Years of Follow-Up. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	20
33	Fixed vs adjusted-dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: A systematic review and meta-analysis. PLoS Neglected Tropical Diseases, 2020, 14, e0008529.	3.0	17
34	Prospective multicenter evaluation of real time PCR Kit prototype for early diagnosis of congenital Chagas disease. EBioMedicine, 2021, 69, 103450.	6.1	14
35	Electrocardiographic Abnormalities and Treatment with Benznidazole among Children with Chronic Infection by Trypanosoma cruzi: A Retrospective Cohort Study. PLoS Neglected Tropical Diseases, 2016, 10, e0004651.	3.0	13
36	A new patient registry for Chagas disease. PLoS Neglected Tropical Diseases, 2020, 14, e0008418.	3.0	8

#	Article	lF	CITATIONS
37	Serological reactivity against T. cruzi-derived antigens: Evaluation of their suitability for the assessment of response to treatment in chronic Chagas disease Acta Tropica, 2021, 221, 105990.	2.0	6
38	Critical analysis of Chagas disease treatment in different countries. Memorias Do Instituto Oswaldo Cruz, 0, $117$ , .	1.6	6
39	Response to `letter to the editor: â€~Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America'´. Expert Review of Anti-Infective Therapy, 2019, 17, 673-675.	4.4	3
40	Benznidazole in Chagas disease study: do the data justify progression to phase 3? – Authors' reply. Lancet Infectious Diseases, The, 2021, 21, 1067.	9.1	2
41	Challenges in Chagas Disease Control Through Transmission Routes. , 2020, , 37-55.		1